Burn Pain – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Burn Pain Market Outlook

Thelansis’s “Burn Pain Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Burn Pain treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Burn Pain Overview

Pain associated with burn and discomfort is an unfortunate part of burn injury and recovery. Burn pain is complex and requires careful assessment by your health care provider in order to find the best treatment. Pain management often requires a multidisciplinary approach that may include both medication and non-medication treatments and involve a team of health providers. There are many different types of burn pain, and each person’s pain is unique. Understanding the type, intensity, and duration of your pain is important for treatment. Types of pain are classified as Acute pain, Breakthrough pain, Resting pain, Chronic Pain, and Neuropathic Pain. It is often difficult to distinguish between changes in background pain and additional pain caused by movement both of which would be regarded as ‘breakthrough pain’. For this reason, breakthrough pain has been dealt with alongside background pain.

• According to a literature survey, each year in the United States, 1.1 million burn injuries require medical attention. Approximately 50,000 of these require hospitalization; 20,000 have major burns involving at least 25 percent of their total body surface, and approximately 4,500 of these people die. Up to 10,000 people in the United States die every year of burn-related infections.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: